| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918653 | Radiotherapy and Oncology | 2014 | 8 Pages |
Abstract
EGFR-targeted EBRIT can improve permanent local tumor control compared to EBRT alone. PET imaging of bioavailability of labeled cetuximab appears to be a suitable predictor for response to EBRIT. This theragnostic approach should be further explored for clinical translation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lydia Koi, Ralf Bergmann, Kerstin Brüchner, Jens Pietzsch, Hans-Jürgen Pietzsch, Mechthild Krause, Jörg Steinbach, Daniel Zips, Michael Baumann,